|
|
Article: Medtronic, Genzyme form j-v for cardiovascular therapies.
- Article from:
- Medical Device Daily
- Article date:
- June 2, 2004
CopyrightCOPYRIGHT 2004 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Medtronic, Genzyme form j-v for cardiovascular therapies
By HOLLAND JOHNSON
Medical Device Daily Associate Managing Editor
In an agreement that appears to bolster the growing trend toward medical device/biotechnology combination products, device giant Medtronic (Minneapolis, Minnesota) and Genzyme (Cambridge, Massachusetts), a large biotech company that focuses on rare genetic diseases as well as other disorders, have formed a joint venture to accelerate the development of new treatments for some of the most intractable forms of cardiovascular disease.
The new venture, which is to be named MG Biotherapeutics, will combine Medtronics ...